AI Three-Item Severity Score Can ID Eczema From Patient-Uploaded Images
By Elana Gotkine HealthDay Reporter
FRIDAY, May 23, 2025 -- An artificial intelligence (AI) Three-Item Severity (TIS) score can identify eczema-affected areas and severity scores from user-uploaded images, according to a research letter published online May 19 in Allergy.
Utako Okata-Karigane, M.D., from the Keio University School of Medicine in Japan, and colleagues developed an AI-based model to assess eczema severity from user-uploaded photos. Three algorithms were trained and integrated: body part detection, skin lesion detection, and severity assessment. The TIS score, a localized severity assessment ranging from 0 to 9, evaluating erythema, edema/papulation, and excoriation, was adopted because the model analyzes representative images rather than full-body images.
A total of 9,656 images with itch scores were included to establish and validate AI-TIS. The researchers found that the trained AI model correctly detected 98 and 100 percent of body parts and eczema areas, respectively; across 220 test images, the model correlated well with TIS scores determined by board-certified dermatologists and/or allergists (R = 0.73). Across 8,556 images, AI-TIS showed a lower correlation with itch intensity on a 0-to-5 numeric rating scale (R = 0.11). In 15 patients, correlations of AI-TIS with TIS, SCORing Atopic Dermatitis (SCORAD), and objective-SCORAD were R = 0.16, 0.4, and 0.53, respectively.
"This study lays the groundwork for future advancements in AI-driven dermatological assessments, enhancing both patient care and clinical research," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Lebrikizumab Efficacious, Safe for Patients With Skin of Color, Eczema
WEDNESDAY, Aug. 13, 2025 -- For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study published online July 15 in the...
Public Believes Dermatologic Side Effects From Cancer Treatment Are Common
TUESDAY, Aug. 12, 2025 -- Most individuals living in underserved communities believe that dermatologic side effects (DSEs) from anticancer therapies (ACTs) occur at high rates...
Novel Treatments Recommended for Management of Atopic Dermatitis in Adults
FRIDAY, July 25, 2025 -- In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.